CD388 is a novel, long-acting, antiviral drug-Fc conjugate (DFC) designed to deliver universal prevention of seasonal and pandemic influenza. Nonclinical studies have shown CD388 to be effective prophylactically against seasonal and pandemic influenza A and B strains in naloxone mouse models of infection.

**RESULTS**

Safety and Tolerability

- Overall profile: well-tolerated up to 900 mg single dose; study in progress with limited follow up at highest doses.
- No treatment-emergent SAEs and no withdrawals due to safety findings.
- Most TEAEs were Grade 1 (90%), few Grade 2, all resolved within the exposure time-frame.
- Incidence of TEAE not dose-dependent.
- No hypersensitivity reactions were observed.
- Few injection site events (pain, IM route mainly), Grade 1, all resolved spontaneously.
- No clinically relevant ECG, vital signs or physical exam abnormalities.

Pharmacokinetics

- IM or SQ CD388 was well absorbed.
- Time of maximum plasma concentrations (Tmax) appeared from 2 to 13 days post dose, and quantifiable concentrations (>LOQ) lasted for months (Figure 2).
- CD388 AUC increased approximately dose proportional for both routes (Figure 3).
- Mean apparent half-life of elimination was ~ 6 to 7 weeks (Table 1).

**DISCUSSIONS / ACKNOWLEDGMENTS**

This study was funded by Janssen R&D.

**FOOTNOTES**

1. Cidara Therapeutics Inc.

2. Janssen R&D